Successful use of long-term follow-up in patients with chronic myeloid leukemia with a deep molecular response at reduced doses of 2nd generation tyrosine kinase inhibitors: clinical cases and literature review

Cover Page

Cite item

Full Text

Abstract

Therapy with tyrosine kinase inhibitors (TKI) allows to achieve a deep molecular response in 60–70% of patients with chronic myeloid leukemia (CML). According to the current guidelines CML patients receive a long-term treatment with TKI in standard dose. The frequently observed adverse effects (AE) of TKI therapy are mostly dose-dependent. A new treatment approach with TKI use in reduced dose is desirable for the CML patients with existing AE or with a high risk of AE occurrence. We report the two cases of successful long-term treatment of CML patients with reduced doses of second generation TKIs. The aim of the TKI dose reduction was to reduce the clinical manifestations of drug toxicities and to prevent the AE.

About the authors

M. A. Gurianova

National Research Center for Hematology

Author for correspondence.
Email: margarita.samtcova@yandex.ru
ORCID iD: 0000-0001-9984-389X

врач-гематолог научно-консультативного отд-ния химиотерапии миелопролиферативных заболеваний

Russian Federation, Moscow

E. Yu. Chelysheva

National Research Center for Hematology

Email: margarita.samtcova@yandex.ru
ORCID iD: 0000-0001-6423-1789

к.м.н., врач-гематолог, вед. науч. сотр. научно-консультативного отд-ния химиотерапии миелопролиферативных заболеваний

Russian Federation, Moscow

O. A. Shukhov

National Research Center for Hematology

Email: margarita.samtcova@yandex.ru
ORCID iD: 0000-0001-5393-0816

к.м.н., врач-гематолог, ст. науч. сотр. научно-консультативного отд-ния химиотерапии миелопролиферативных заболеваний

Russian Federation, Moscow

A. G. Turkina

National Research Center for Hematology

Email: margarita.samtcova@yandex.ru
ORCID iD: 0000-0001-9947-2371

д.м.н., проф., врач-гематолог, зав. научно-консультативным отд-нием химиотерапии миелопролиферативных заболеваний

Russian Federation, Moscow

References

  1. Туркина А.Г., Новицкая Н.В., Голенков А.К. и др. Регистр больных хроническим миелолейкозом в Российской Федерации: от наблюдательного исследования к оценке эффективности терапии в клинической практике. Клиническая онкогематология. 2017;10(3):390-401 [Turkina AG, Novickaya NV, Golenkov AK, et al. Chronic myeloid leukemia patient registry in the Russian Federation: from observational studies to the efficacy evaluation in clinical practice. Klinicheskaya onkogematologiya. 2017;10(3):390-401 (In Russ.)]. doi: 10.21320/2500-2139-2017-10-3-390-401
  2. Sasaki K, Strom SS, O’Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;5:e186-93. doi: 10.1016/S2352-3026(15)00048-4. PMID: 26688093.
  3. Hehlmann R, Lauseker M, Saußele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398-406. doi: 10.1038/leu.2017.253
  4. Шухов О.А., Туркина А.Г., Челышева Е.Ю. и др. Отдаленные результаты терапии ингибиторами тирозинкиназ у больных хроническим миелолейкозом в ранней и поздней хронической фазе. Клиническая онкогематология. 2016;9:368 [Shukhov OA, Turkina AG, Chelysheva EYu, et al. Long-term results of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients in early and late chronic phase. Klinicheskaya onkogematologiya. 2016;9:368 (In Russ.)].
  5. Saussele S, Richter J, Guilhot J, et al.; EURO-SKI investigators. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747-57. doi: 10.1016/S1470-2045(18)30192-X
  6. Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298-305. doi: 10.1200/jco.2016.68.2914
  7. Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846-54. doi: 10.1182/blood-2016-09-742205
  8. Chelysheva E, Petrova A, Shukhov O, et al. First interim analysis of the russian multicenter prospective study ru-ski: discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia and deep molecular response. 23rd Congress of European Hematology Association. Hematologica. 2018;2(S1):PF374.
  9. Туркина А.Г., Челышева Е.Ю., Шуваев В.А. и др. Результаты наблюдения больных хроническим миелолейкозом с глубоким молекулярным ответом без терапии ингибиторами тирозинкиназ. Терапевтический архив. 2017;89(12):86-96 [Turkina AG, Chelysheva EYu, Shuvaev VA, et al. Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy. Therapeutic Archive. 2017;89(12):86-96 (In Russ.)]. doi: 10.17116/terarkh2017891286-96
  10. Зейфман А.А., Челышева Е.Ю., Туркина А.Г., Чилов Г.Г. Роль селективности ингибиторов тирозинкиназ в развитии побочных эффектов при терапии хронического миелолейкоза. Клиническая онкогематология. 2014;7(1):16 [Zejfman AA, Chelysheva EYu, Turki- na AG, Chilov GG. Role of tyrosine-kinase inhibitor selectivity in development of adverse effects during treatment of chronic myeloid leukemia. Klinicheskaya onkogematologiya. 2014;7(1):16 (In Russ.)].
  11. Ломаиа Е.Г., Романова Е.Г., Сбитякова Е.И., Зарицкий А.Ю. Эффективность и безопасность ингибиторов тирозинкиназ 2-го поколения (дазатиниб, нилотиниб) в терапии хронической фазы хронического миелолейкоза. Онкогематология. 2013;2:22-33 [Lomaia EG, Romanova EG, Sbityakova EI, Zarickij AY. Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia. Onkogematologiya. 2013;2:22-33 (In Russ.)].
  12. Лазорко Н.С., Ломаиа Е.Г., Романова Е.Г. и др. Ингибиторы тирозинкиназ второго поколения и их токсичность у больных в хронической фазе хронического миелолейкоза. Клиническая онкогематология. 2015;8(3):302-8 [Lazorko NS, Lomaia EG, Romanova EG, et al. Second generation tyrosine kinase inhibitors and their toxicity in treatment of patients in chronic phase of chronic myeloid leukemia. Klinicheskaya onkogematologiya. 2015;8(3):302-8 (In Russ.)].
  13. Kantarjian H, Pasquini R, Lévy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009;115:4136-47. doi: 10.1002/cncr.24504
  14. Quinta´s-Cardama A, Kantarjian H, O’Brien S, et al. Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure. J Clin Oncol. 2007;1;25(25):3908-14. doi: 10.1200/JCO.2007.12.032
  15. De Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141(5):745-7. doi: 10.1111/j.1365-2141.2008.07108
  16. Троицкая Е.А., Вельмакин С.В., Кобалава Ж.Д. Концепция сосудистого возраста: новый инструмент оценки сердечно-сосудистого риска. Артериальная гипертензия. 2017;23(2):160-71 [Troickaya EA, Vel’makin SV, Kobalava ZhD. Concept of vascular age: new tool in cardiovascular risk assessment. Arterial’naya gipertenziya. 2017;23 (2):160-71 (In Russ.)]. doi: 10.18705/1607-419X-2017-23-2-160-171
  17. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044-54. doi: 10.1038/leu.2016.5
  18. Cortes JE, Saglio G, Kantarjian H, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;10,34(20):2333-40. doi: 10.1200/jco.2015.64.8899
  19. Шухов О.А., Туркина А.Г., Челышева Е.Ю. и др. Терапия хронического миелолейкоза согласно современным рекомендациям: результаты пилотного проспективного исследования «Ранняя индукционная терапия и мониторинг» (РИТМ). Клиническая онкогематология. 2019;12(2):194-201 [Shukhov OA, Turkina AG, Chelysheva EYu, et al. Treatment of chronic myeloid leukemia according to current guidelines: the results of the pilot prospective study “early induction therapy and monitoring” (РИТМ). Klinicheskaya onkogematologiya. 2019;12(2):194-201 (In Russ.)]. doi: 10.21320/2500-2139-2019-12-2-194-201
  20. Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017;4:e310-16. doi: 10.1016/s2352-3026(17)30066-2
  21. Rea D, Cayuela J, Dulucq S, Etienne G. Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: a real life observational study (NILO-RED). Blood. 2017;130(1):318. 590th ASH, Atlanta.
  22. Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6(7):e375-e383. doi: 10.1016/S2352-3026(19)30094-8
  23. Naqvi K, Jabbour E, Skinner J, et al. Long-Term Follow-Up of Lower Dose Dasatinib (50 mg Daily) as Frontline Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. Cancer. 2020;126(1):67-75. doi: 10.1002/cncr.32504

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies